• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186834 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
# {7 D- K0 E# w" P& a2 K5 u- [8 r- Z9 G! Y

! C! `- v& a( o6 r- h) R: oSub-category:# ?" q3 [- ~  B+ I% i: `
Molecular Targets 7 z1 ?2 e7 D) }, V* Q. e

# `' r  Q  ^/ o5 N. A/ _6 N% }, K% c: r5 A9 W, C) }& H8 {9 x
Category:
) v$ M- X8 R: w+ LTumor Biology
$ o7 L9 ]/ l% G! _3 K
6 Y. B( M8 ]/ c& i6 l8 g0 C$ e/ A) y& O) Q0 f3 v+ R1 m
Meeting:
5 C8 i. K4 ]0 i7 j- B4 b2011 ASCO Annual Meeting
" u9 }* U( `7 p9 N3 d, F* F! T- i0 V8 M
% e/ z3 ~" C( o3 M
Session Type and Session Title:
4 t6 T0 e6 F" D, [Poster Discussion Session, Tumor Biology
1 U  K8 N1 L8 j: c
) s7 d$ h0 g4 T( P& Q5 x/ H3 d  l0 y5 a, ?6 J# X! @
Abstract No:
: N! A4 b# {( j* B9 M10517
; I6 d8 I+ w% O$ E4 R0 _6 S/ Y$ H$ u9 B+ {  g$ F

9 c( w4 o( k& ^( V- {7 \) U0 N1 bCitation:, u) V% t' ?/ B! x8 @
J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 S* `* P4 k, _  Y+ p1 |/ N/ D# F1 ~* s# J

) F+ W' m7 ]! E- b4 ]Author(s):; q% r- k& C# D1 H! g3 X* d: J9 O
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) {- J: s1 d7 _8 J5 Q: c9 ?

" G2 T9 ~- f- X
: W2 w9 W  M% ]. m3 ]; c: R, [5 J3 L0 h6 b" F
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.3 B" G, b/ J$ Z' c% z/ E6 T

6 s, Z& _0 h# h$ e4 e* IAbstract Disclosures
+ C2 K: h. g8 D4 |' f# c* {% L: d# I7 d" J9 A; Q: x: A0 K, }
Abstract:
+ h9 s0 Q$ G0 r) W1 h- ?, n- L7 G3 T) L2 R
* k- ]7 ~% Z& b9 W  p( D
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
3 ^2 ^8 u3 D7 ]: E3 Z' g
; z; r1 t' {0 {1 p. `- |
1 P8 I+ U: z, I; H
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
" t2 g7 Z/ o; U; y! u! n( f$ O- r没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

5 X' I& y, F! S) a! C. d, b化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - j3 o/ K% ^: _6 M
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。( ?3 y! ?& n# r% I9 Q
ALK一个指标医院要900多 ...

3 e$ q) S* @* Y+ P平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?  l4 M- a: Q% w7 p1 q7 C
  X" w0 B; N7 {0 i8 C' W+ L! k* h# X
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表